Myositis Clinical Trial
Official title:
Characterizing Myositis With 68Ga-FAPI PET/CT
To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis and evaluation of systemic involvement in idiopathic inflammatory myopathies (IIM)/myositis, and compared the results with those of 18F-FDG PET/CT.
Inflammatory myopathies (IIM), collectively known as myositis, are heterogeneous systemic autoimmune disorders characterized by muscle inflammation, and frequently accompanied by extra-muscular manifestations that affect the skin, lung, and joints. Prevalence of underlying malignancy is high in patients with IIM. 68Ga-FAPI has been developed as tracers specific for fibroblast-activation protein (FAP), which is overexpressed in activated fibroblasts in various type of cancers and autoimmune diseases, such as rheumatoid arthritis, IgG4-related diseases and interstitial lung diseases. Recently the investigators have published articles of the application of 68Ga-FAPI in IgG4-related disease and rheumatoid arthritis, which showed it was more sensitive than FDG in detecting a certain type of inflammation, and the potential utility of FAP-targeted PET/CT imaging for disease assessment in myositis have been reported in a case recently. Thus, this prospective study is going to investigate utility of 68Ga-FAPI PET/CT in diagnosis, disease assessment including skeletal muscle involvement, cardiac involvement, interstitial lung diseases and potential underlying cancer screening, response to treatment and prognosis, compared with 18F-FDG PET/CT. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
| Completed |
NCT06300983 -
Effectiveness of a Psychoeducational Intervention on Myositis Patients' Quality of Life and Well-Being
|
N/A | |
| Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
| Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
| Active, not recruiting |
NCT02468895 -
MYOPROSP - a Prospective Cohort Study in Myositis
|
||
| Recruiting |
NCT01501019 -
Exercise in Sjogren, Myositis and Takayasu's Arteritis
|
N/A | |
| Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
| Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
| Not yet recruiting |
NCT01702870 -
Diagnostic Accuracy of MR in Myositis
|
N/A | |
| Terminated |
NCT03937856 -
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
|
N/A | |
| Completed |
NCT03440034 -
Study of Pioglitazone in Sporadic Inclusion Body Myositis
|
Phase 1 | |
| Recruiting |
NCT05895786 -
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
|
Phase 3 | |
| Completed |
NCT00001331 -
Genetic and Family Studies of Inherited Muscle Diseases
|
N/A | |
| Terminated |
NCT04309227 -
Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations
|
N/A | |
| Completed |
NCT03059394 -
Validation of Rehab Assessments in Myositis Patients
|
N/A | |
| Completed |
NCT00106184 -
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
|
Phase 2 | |
| Recruiting |
NCT04367350 -
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
|
||
| Completed |
NCT01734369 -
Environmental Risk Factors for Myositis in Military Personnel
|
||
| Recruiting |
NCT02450396 -
Pregnancy and Medically Assisted Conception in Rare Diseases
|
||
| Recruiting |
NCT03912428 -
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
|
Phase 1 |